Enveric Biosciences Presents Compelling Preclinical Data On Lead Compound EB-003 At 7th Neuropsychiatric Drug Summit

Enveric Biosciences ENVB recently announced that research highlighting the Company's lead compound, EB-003, is being presented at the 7^th Neuropsychiatric Drug Summit.

EB-003 is a promising neuroplastogenic and non-hallucinogenic N, N-Dimethyltryptamine (DMT) analog drug candidate that elicited beneficial outcomes in preclinical models of anxiety and depression. The conference is being held at the Hilton Boston Back Bay in Boston, MA on September 24-26, 2024.

The presentation titled, "Non-hallucinogenic and neuroplastogenic DMT analog imparts positive behavioral outcomes in mice," addresses the criteria researchers evaluated in the design and development of EB-003 as a non-hallucinogenic derivative of DMT for the treatment of neuropsychiatric disorders, including depression and anxiety.

The poster highlights key preclinical data involving EB-003, including two mouse models demonstrating the effectiveness of EB-003 in reducing anxiety and depression, and research examining head twitch response (HTR), a behavioral proxy in rodents for hallucinogenic effects in humans.

This data adds to the library of research supporting the advancement of EB-003 as Enveric's lead drug candidate. Recently, Enveric reported preclinical data confirming the oral bioavailability of EB-003 and its ability to produce brain exposure at therapeutically relevant levels. Enveric expects to file an Investigational New Drug (IND) application for EB-003 by the third quarter of 2025 and initiate clinical development by the end of 2025.

"The research being presented at the 7^th Neuropsychiatric Drug Summit was foundational in our selection of EB-003 as our lead product candidate given its potential ability to treat resistant mental health disorders without the hallucinogenic effect typically associated with DMT-based molecules and related analogs," said Joseph Tucker, Ph.D., Chief Executive Officer of Enveric. 

"Coupled with recent evidence demonstrating the ability of EB-003 to achieve optimal brain exposure after oral dosing, this research affirms our belief that EB-003 is highly differentiated from similar drugs in development and has the potential to be a significant value driver for Enveric and our shareholders."

Image sourced from Shutterstock

This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice.